DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes

Information source: Johns Hopkins University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Type 1 Diabetes; Hypoglycemia

Intervention: Evening only administration of insulin glargine (Drug); Morning only administration of insulin glargine (Drug); split dose insulin glargine (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: Johns Hopkins University

Official(s) and/or principal investigator(s):
Christopher D Saudek, MD, Principal Investigator, Affiliation: Johns Hopkins University
Ari S Eckman, MD, Study Director, Affiliation: Johns Hopkins University

Overall contact:
Christopher D Saudek, MD, Phone: 410-955-2132, Email: csaudek@jhu.edu


This research is a prospective, randomized, cross-over study that is being done to compare the effect of morning only, evening only and twice daily insulin glargine (Lantus®) on hypoglycemia (blood glucose level <70 mg/dL) as measured by continuous glucose monitoring (CGM) in patients with type 1 diabetes.

Clinical Details

Official title: Comparison of Glycemic Response to Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes Using Continuous Glucose Monitoring

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome:

Time spent (mean number of minutes per 24 hour day) in hypoglycemic range (<70mg/dl)

Change in the mean minutes per 24 hour day in the hyperglycemic range of > 180 mg/dL.

Secondary outcome:

Time spent in nocturnal hypoglycemic range (midnight to 6am)

Time spent in severe hypoglycemic range (<50 mg/dl)

Episodes of clinical hypoglycemia (symptoms)

Removal from study due to unacceptable hypoglycemia

Overall number of hypoglycemic episodes (instances of glucose levels <70 mg/dL)

Determine which regimen of glargine insulin preparation best reduces the propensity for nocturnal hypoglycemia

Glucose levels at fixed times of day (morning, dinner, bedtime) will be compared

Detailed description: Over the course of the 6 week study, patients will take insulin glargine in each of 3 different times: only in the morning, only at night, and half in the morning, half at night. After 2 weeks taking the insulin in one regimen, patients will be switched to another regimen. Through the whole study, patients will be injecting themselves twice daily, and neither the patient nor the treating doctor will know which vials contain the insulin and which have only saline (placebo). The vials will be labeled MORNING or EVENING. Patients will continue to take their mealtime, short acting insulin doses. Additionally, patients will wear a continuous glucose monitor (CGM) which will be masked. Before the study, patients will be taught about how to use the CGM, and keep it taped to their abdomen. The site that the CGM inserts into their abdomen will need to be changed every 5 days. We will know if a patients' blood sugar goes low even if the patient did not feel the low. Patients will still have to self-monitor their blood sugar levels at-least four times in five days, to calibrate the CGM.


Minimum age: 18 Years. Maximum age: 90 Years. Gender(s): Both.


Inclusion Criteria:

- Adult men and women above age 18 with a diagnosis of type 1 diabetes mellitus

- On multiple insulin injections, including a long acting or intermediate acting

insulin preparation and mealtime short acting insulin preparation.

- Clinical history consistent with hypoglycemia

- Hba1c <9. 0%

Exclusion Criteria:

- Patients with type 2 diabetes mellitus

- Patients on insulin pump

- Poor control of diabetes (HbA1c > 9. 0%)

- Pregnancy (women of childbearing age will undergo a pregnancy test at the start of

the study and will be advised to use birth control methods during the study). Insulin glargine has been reported to have teratogenic effects in animal models, and therefore should only be used during pregnancy if clearly needed.

- Serious co-morbidities that, in clinical opinion of the investigators, could affect

pharmacokinetics of glargine (e. g., CRF) or safety (e. g., recent CAD)

Locations and Contacts

Christopher D Saudek, MD, Phone: 410-955-2132, Email: csaudek@jhu.edu

Johns Hopkins Hospital, Baltimore, Maryland 21287, United States
Additional Information

Related publications:

Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase HP. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 2004 Oct;66(1):49-56.

Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006 Aug;23(8):879-86.

Starting date: March 2009
Last updated: March 25, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017